Market Place
Sourcing Support
All News #Library
Biotech
Synthekine, Merck Launch STK-012/Keytruda Trial for NSCLC Cancer
26 Feb 2026 //
BUSINESSWIRE
First Patient Dosed in SYNERGY-101 Ph2 Trial of STK-012
13 Nov 2025 //
BUSINESSWIRE
Synthekine Reveals Positive Phase 1A/1B Trial Results
07 Nov 2025 //
BUSINESSWIRE
Synthekine to Present STK-012 Combo Data in NSCLC at SITC 2025
30 Oct 2025 //
BUSINESSWIRE
Synthekine`s Ph 1 Data for CD19 CAR-T & IL-2 Therapy at ASH 2024
09 Dec 2024 //
BUSINESSWIRE
Synthekine Presents STK-012 IL-2 Data at 39th SITC 2024
08 Nov 2024 //
BUSINESSWIRE
Synthekine Reports Positive Results from STK-012 Trial
09 Apr 2024 //
BUSINESSWIRE
Synthekine Announces IND Clearance for CD19 CAR-T and Ortho IL-2, SYNCAR-001
26 Mar 2024 //
BUSINESSWIRE
Synthekine Announces Presentation of Results from Phase 1a/1b Trial of STK-012
07 Mar 2024 //
BUSINESSWIRE
First Patient Dosed in Phase 1b Trial of Synthekine’s ?/? Biased IL-2, STK-012
28 Sep 2023 //
BUSINESSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.